Currently out of the existing stock ratings of Tazeen Ahmad, 181 are a BUY (62.85%), 70 are a HOLD (24.31%), 37 are a SELL (12.85%).

Tazeen Ahmad

Work Performance Price Targets & Ratings Chart

Analyst Tazeen Ahmad, currently employed at BAML, carries an average stock price target met ratio of 59.01% that have a potential upside of 30.53% achieved within 168 days.

Tazeen Ahmad’s has documented 581 price targets and ratings displayed on 52 stocks. The coverage is on Healthcare, Industrials sectors.

Most recent stock forecast was given on APLS, Apellis Pharmaceuticals at 21-Jan-2026.

Wall Street Analyst Tazeen Ahmad

Analyst best performing recommendations are on SRZN (SURROZEN).
The best stock recommendation documented was for SRZN (SURROZEN) at 11/17/2022. The price target of $15 was fulfilled within 1 day with a profit of $1.65 (9.91%) receiving and performance score of 99.1.

Average potential price target upside

of $89.99 (19.49%) on ARGX (ARGENX NV ADR).
of $34.8 (30.4%) on GWPH (GW PHARMACEUTICALS PLC).
of $33.37 (15.39%) on ALNY (ALNYLAM PHARMACEUTICALS).

ACAD ACADIA Pharmaceuticals ALNY Alnylam Pharmaceuticals BNTX BioNTech SE FOLD Amicus Therapeutics FULC Fulcrum Therapeutics GRTX Galera Therapeutics GWPH GW Pharmaceuticals plc INCY yte NBIX Neurocrine Biosciences PRLD Prelude Therapeutics PTCT PTC Therapeutics RARE Ultragenyx RYTM Rhythm Pharmaceuticals SAGE Sage Therapeutic ASND Ascendis Pharma AS CRTX Cortexyme ORPH Orphazyme A/S SRPT Sarepta Therapeutics BCRX BioCryst Pharmaceuticals PRTA Prothena plc SRZN Surrozen TBPH Theravance Biopharma ADCT ADC Therapeutics SA FATE Fate Therapeutics ADMS Adamas Pharmaceuticals AKUS Akouos ARGX argenx NV ADR CLVS Clovis Oncology CYT Cyteir Therapeutics ETN Eaton PLC KALA Kala Pharmaceuticals MCRB Seres Therapeutics PYXS Pyxis Oncology SGEN Seagen SQZ Sqz Biotechnologies Co ZGNX Zogenix ANNX Annexon ARVN Arvinas PRAX Praxis Precision Medicines ACHL Achilles Therapeutics PLC ADR APLS Apellis Pharmaceuticals CERE Cerevel Therapeutics Holdings PHVS Pharvaris BV FDMT 4D Molecular Therapeutics INZY Inozyme Pharma MRUS Merus BV PEPG PepGen Ltd IMMU Immunomedics DNLI Denali Therapeutics OCUL Ocular Therapeutix PRNB Principia Biopharma STRO Sutro Biopharma

Show more stocks

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score